Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women

PHASE3CompletedINTERVENTIONAL
Enrollment

749

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

July 31, 2007

Conditions
Sexual Dysfunctions, Psychological
Interventions
DRUG

Flibanserin

flibanserin flexible dosing

Trial Locations (65)

Unknown

511.74.01051 Boehringer Ingelheim Investigational Site, Birmingham

511.74.01027 Boehringer Ingelheim Investigational Site, Mobile

511.74.01029 Boehringer Ingelheim Investigational Site, Scottsdale

511.74.01031 Boehringer Ingelheim Investigational Site, Tucson

511.74.01004 Boehringer Ingelheim Investigational Site, Jonesboro

511.74.01053 Boehringer Ingelheim Investigational Site, Little Rock

511.74.01033 Boehringer Ingelheim Investigational Site, Palm Springs

511.74.01003 Boehringer Ingelheim Investigational Site, Palo Alto

511.74.01015 Boehringer Ingelheim Investigational Site, Sacramento

511.74.01013 Boehringer Ingelheim Investigational Site, San Diego

511.74.01052 Boehringer Ingelheim Investigational Site, Torrance

511.74.01022 Boehringer Ingelheim Investigational Site, Aurora

511.74.01046 Boehringer Ingelheim Investigational Site, Denver

511.74.01002 Boehringer Ingelheim Investigational Site, Groton

511.74.01023 Boehringer Ingelheim Investigational Site, Middlebury

511.74.01009 Boehringer Ingelheim Investigational Site, West Hartford

511.74.01035 Boehringer Ingelheim Investigational Site, Newark

511.74.01039 Boehringer Ingelheim Investigational Site, Coral Gables

511.74.01019 Boehringer Ingelheim Investigational Site, Gainesville

511.74.01044 Boehringer Ingelheim Investigational Site, Hollywood

511.74.01001 Boehringer Ingelheim Investigational Site, Hudson

511.74.01043 Boehringer Ingelheim Investigational Site, Pembroke Pines

511.74.01032 Boehringer Ingelheim Investigational Site, St. Petersburg

511.74.01036 Boehringer Ingelheim Investigational Site, Roswell

511.74.01047 Boehringer Ingelheim Investigational Site, Champaign

511.74.01038 Boehringer Ingelheim Investigational Site, Evansville

511.74.01014 Boehringer Ingelheim Investigational Site, Lexington

511.74.01007 Boehringer Ingelheim Investigational Site, Baton Rouge

511.74.01024 Boehringer Ingelheim Investigational Site, Rockland

511.74.01030 Boehringer Ingelheim Investigational Site, Ann Arbor

511.74.01056 Boehringer Ingelheim Investigational Site, Bingham Farms

511.74.01010 Boehringer Ingelheim Investigational Site, St Louis

511.74.01012 Boehringer Ingelheim Investigational Site, Billings

511.74.01045 Boehringer Ingelheim Investigational Site, Omaha

511.74.01041 Boehringer Ingelheim Investigational Site, Las Vegas

511.74.01055 Boehringer Ingelheim Investigational Site, Reno

511.74.01018 Boehringer Ingelheim Investigational Site, Poughkeepsie

511.74.01011 Boehringer Ingelheim Investigational Site, Rochester

511.74.01048 Boehringer Ingelheim Investigational Site, Winston-Salem

511.74.01021 Boehringer Ingelheim Investigational Site, Cincinnati

511.74.01042 Boehringer Ingelheim Investigational Site, Columbus

511.74.01050 Boehringer Ingelheim Investigational Site, Edmond

511.74.01006 Boehringer Ingelheim Investigational Site, Eugene

511.74.01034 Boehringer Ingelheim Investigational Site, Medford

511.74.01040 Boehringer Ingelheim Investigational Site, Pittsburgh

511.74.01017 Boehringer Ingelheim Investigational Site, Anderson

511.74.01057 Boehringer Ingelheim Investigational Site, Knoxville

511.74.01008 Boehringer Ingelheim Investigational Site, Nashville

511.74.01016 Boehringer Ingelheim Investigational Site, Plano

511.74.01020 Boehringer Ingelheim Investigational Site, San Antonio

511.74.01005 Boehringer Ingelheim Investigational Site, Salt Lake City

511.74.01026 Boehringer Ingelheim Investigational Site, Norfolk

511.74.01037 Boehringer Ingelheim Investigational Site, Renton

511.74.01028 Boehringer Ingelheim Investigational Site, Spokane

511.74.01049 Boehringer Ingelheim Investigational Site, Milwaukee

511.74.02011 Boehringer Ingelheim Investigational Site, Coquitlam

511.74.02009 Boehringer Ingelheim Investigational Site, Kelowna

511.74.02012 Boehringer Ingelheim Investigational Site, Winnipeg

511.74.02006 Boehringer Ingelheim Investigational Site, St. John's

511.74.02004 Boehringer Ingelheim Investigational Site, Halifax

511.74.02010 Boehringer Ingelheim Investigational Site, Kingston

511.74.02003 Boehringer Ingelheim Investigational Site, Oakville

511.74.02002 Boehringer Ingelheim Investigational Site, Ottawa

511.74.02007 Boehringer Ingelheim Investigational Site, Ottawa

511.74.02008 Boehringer Ingelheim Investigational Site, Montreal

All Listed Sponsors
lead

Sprout Pharmaceuticals, Inc

INDUSTRY

NCT00277914 - Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women | Biotech Hunter | Biotech Hunter